{
    "relation": [
        [
            "",
            "15 Mcg H1N1 Vaccine",
            "30 Mcg H1N1 Vaccine"
        ],
        [
            "Description",
            "15 mcg inactivated influenza H1N1 vaccine administered intramuscularly on Day 0 and Day 21.",
            "30 mcg inactivated influenza H1N1 vaccine administered intramuscularly on Day 0 and Day 21."
        ]
    ],
    "pageTitle": "H1N1 Vaccine at Two Dose Levels in HIV Positive Adults - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00992433?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988650.6/warc/CC-MAIN-20150728002308-00093-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 869687811,
    "recordOffset": 869671873,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were HIV-positive adult males and females recruited from existing patient populations and from the communities at large around the clinical sites. Participants were enrolled between 19Nov2009 and 23Apr2010. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: Inactivated Influenza H1N1 vaccine Intervention: Influenza Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional Study Type:",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 15 Mcg H1N1 Vaccine \u00a0 \u00a0 30 Mcg H1N1 Vaccine \u00a0 STARTED \u00a0 \u00a0 95 \u00a0 \u00a0 97 \u00a0 COMPLETED \u00a0 \u00a0 91 \u00a0 \u00a0 90 \u00a0 NOT COMPLETED \u00a0 \u00a0 4 \u00a0 \u00a0 7 \u00a0 \u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered.",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}